Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD


June 24, 2021

Compared with SGLT2 inhibitors alone, combination therapy with GLP-1 receptor agonists plus SGLT2 inhibitors has been associated with greater glucose lowering, weight loss, and systolic blood pressure reduction; however, combined treatment increases the risk for gastrointestinal disorders. Gastrointestinal side effects are not often observed with DPP-4 inhibitors.

No increased risk for urinary tract infection nor hypoglycemia has been observed with SGLT2 inhibitors or DPP-4 inhibitors.

The combination of SGLT2 inhibitors plus DPP-4 inhibitors lowers the risk for genital infection compared with an SGLT2 inhibitor alone. Combination therapy also effectively lowers glycemia.

Learn more about the workup of type 2 diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: